Table 2.

Change in each endpoint after FP in low and high dose treatment arms

	Low dose FP (n = 11)	High dose FP (n = 11)
	Mean (SD)	Mean (SD)	p value
change in FEV1 (L)	0.291 (0.512)	0.364 (0.356)	0.703
change in percent predicted FEV1 (%)	6.5 (11.1)	8.0 (7.1)	0.719
change in FEV1/FVC ratio after FP (%)	3.5 (4.6)	5.7 (6.1)	0.336
change in Bronchodilator response (%)	0.1 (7.8)	2.7 (5.5)	0.376
change in log RDR (%/mg)	0.955 (0.530)	0.751 (0.433)	0.335
change in log exhaled NO (ppb)	0.307 (0.259)	0.427 (0.304)	0.331
Mannitol Doubling Dose Difference	3.2 (1.8)	2.5 (1.4)	0.335
change in basement membrane thickness (μm)	-0.27 (1.08)	0.56 (1.38)	0.133
	Median (IQR)	Median (IQR)	p value
change in Juniper ACQS	0.5 (0-1.0)	1.0 (0-1.0)	0.969
change in LPS induced TNF-alpha mRNA (Ct)	0.1 (-0.7-1.7)	0.7 (-0.4-2.1)	0.797
change in LPS induced GM-CSF mRNA (Ct)	1.7 (-1.4-3.8)	2.9 (-1.9-5.0)	0.748
change in LPS induced IL-1ra mRNA (Ct)	3.2 (2.0-4.3)	3.3 (1.3-5.7)	0.606
change in LPS induced IL-10 mRNA (Ct)	-0.6 (-1.2-1.7)	0.5 (-0.7-1.2)	0.332
change in LPS induced TNF-alpha protein (pg/mL)	830 (-3888-1302)	-2860 (-9173-2716)	0.395
change in LPS induced GM-CSF protein (pg/mL)	307 (-414-2986)	418 (-619-1154)	0.768
change in LPS induced IL-1ra protein (pg/mL)	4035 (1493-58151)	10166 (-1631-15164)	0.922
change in LPS induced IL-10 protein (pg/mL)	0.5 (-75.6-19.2)	1.3 (-44.5-79.7)	0.622

SD = standard deviation, IQR = interquartile range, Ct = threshold cycle